SCHEMBL5455325

SCHEMBL5455325

CC1=NN(Cc2ccccc2)C(=O)C1=Cc1ccc(O)c(O)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.66
MEN1 O00255 7/20 0.66
L3MBTL1 Q9Y468 5/20 0.66
ALDH1A1 P00352 4/20 0.66
TDP1 Q9NUW8 3/20 0.66
MAPT P10636 2/20 0.66
KDM4E B2RXH2 2/20 0.66
ALPL P05186 1/20 0.66
ALPI P09923 1/20 0.66
ALPG P10696 1/20 0.66
EP300 Q09472 5/20 0.61
GAA P10253 3/20 0.50
POLB P06746 3/20 0.50
HSP90AA1 P07900 1/20 0.50
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
GALK1 P51570 2/20 0.49
RECQL P46063 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5786717 1.00 KMT2A (0.66) KMT2AMEN1L3MBTL1ALDH1A1TDP1
SCHEMBL3678657 0.79 KMT2A (0.72) KMT2AMEN1L3MBTL1ALDH1A1TDP1
SCHEMBL3678658 0.79 KMT2A (0.72) KMT2AMEN1L3MBTL1ALDH1A1TDP1
SCHEMBL5476898 0.73 KMT2A (0.58) KMT2AMEN1L3MBTL1ALDH1A1TDP1
SCHEMBL5476893 0.73 KMT2A (0.58) KMT2AMEN1L3MBTL1ALDH1A1TDP1
SCHEMBL6733169 0.73 ALDH1A1 (0.54) KMT2AMEN1L3MBTL1ALDH1A1TDP1
SCHEMBL419547 0.73 KMT2A (0.60) KMT2AMEN1L3MBTL1ALDH1A1TDP1
SCHEMBL445330 0.73 KMT2A (0.60) KMT2AMEN1L3MBTL1ALDH1A1TDP1
SCHEMBL445329 0.69 PRMT5 (0.45) KMT2AMEN1L3MBTL1ALDH1A1TDP1
SCHEMBL445331 0.69 PRMT5 (0.45) KMT2AMEN1L3MBTL1ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 KMT2A 2948/4885MEN1 2892/4885L3MBTL1 1479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.